Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2010

01-04-2010 | Review Article

Highlights of the EANM Congress Barcelona 2009: increasing our impact in diagnostic imaging

Author: Isabel Roca

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2010

Login to get access

Abstract

The EANM Congress 2009 took place in Barcelona from 10 to 14 October under the chairmanship of Dr. Martin-Comin. As always, the meeting was successful with high-level scientific content and a great number of participants. In spite of the economic crisis, industry made an important contribution presenting new revolutionary equipment and tracers, and in particular the pharmaceutical industry has increased its involvement in our speciality. This article is a brief summary of the major scientific contributions presented at the annual congress 2009, highlighting the fields of nuclear medicine at a higher level of development, including those with an increased clinical impact (especially oncology, but also cardiology, neurology and other clinical sciences), new detectors and multimodality imaging, and those fields showing important progress, including radiochemistry and pharmacy (with the development of new tracers and increased collaboration of industry).
Literature
1.
Bischof Delaloye A, Carrió I, Cuocolo A, Knapp W, Gourtsoyiannis N, McCall I, et al. White paper of the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR) on multimodality imaging. Eur J Nucl Med Mol Imaging 2007;34(8):1147–51.PubMedCrossRef
2.
Israel O. Indications, results and pitfalls of PETCT in posttreatment follow-up of lung cancer and H&N cancer. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP211.
3.
Shirvan A, Allen A, Steinmetz A, Reshef A, Akselrod A, Hoglund J, et al. Apoptosis imaging in clinical trials: dynamic PET studies with 18F-ML-10. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP296.
4.
Yamane T, Sakamoto S, Senda M. Clinical impact of C-11 methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:P077.
5.
Toubaru S, Yoshikawa K, Ohashi S, Hasebe M, Ishikawa H, Sagou K, et al. Usefulness of C-11 methionine PET/CT for predicting recurrence, metastasis and prognosis of patients with lung cancer treated by carbon ion radiotherapy. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:P116.
6.
Rousseau C, Eugene T, Testard A, Campion L, Bodet-Milin C, Oudoux A, et al. Comparison of different indicators for dual-time-point interpretation to improve specificity of PET/CT imaging. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP155.
7.
Intriago B, Danus M, Calvo C, Trampal C, Escobar J, Montero M, et al. Advantages and disadvantages of combining a protocol of PET/low-dose-CT with an additional contrast media enhanced CT (CE-CT). Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP156.
8.
Brepoels L, Stroobants S, De Wolf-Peeters C, Mortelmans L, De Groot T, Verhoef G. MicroPET evaluation of FDG- and FLT-uptake after cyclophosphamide and mTOR-Inhibition. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP291.
9.
Rendl G, Rettenbacher L, Holzmannhofer J, Seifen T, Datz L, Schneider A, et al. Comparison of the PET-tracer F-18 FLT and F-18 FDG in patients with rectal cancer: diagnostic value before and after neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP537.
10.
Papathanasiou N, Taylor S, Groves A, Mapanzure L, Robinson C, Endozo R, et al. Simultaneous 18FDG PET improves diagnostic performance of non-laxative CT colonography in polyp detection in high-risk patients for colorectal cancer. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP538.
11.
Dominguez-Prado I, Arbizu J, Garrastachu P, Gonzalez-Forero M, Vigil C, Largo A, et al. Clinical experience with 18F-DOPA-PET/CT in the diagnosis and localization of congenital hyperinsulinism. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP599.
12.
Prasad V, Kaemmerer D, Hommann M, Hoersch D, Zachert C, Baum RP. Management of neuroendocrine tumours of the rectum (rNET) with Ga-68 somatostatin receptor PET/CT (SR-PET/CT) and peptide receptor radionuclide therapy (PRRT). Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP229.
13.
Wild D, Bomanji JB, Reubi JC, Maecke HR, Caplin ME, Ell PJ. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT in the detection of GEP NETs. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP231.
14.
Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European Centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP484.
15.
Caroli P, Fantini L, Ambrosini V, Lopci E, Musto A, Maffione A, et al. The role of positron emission tomography scan with 18Ffluorodeoxyglucose (FDG-PET) as the chief predictor of autologous stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:132.
16.
Muylle K, Vugts DJ, Meuleman N, Ghanem G, Bourgeois P, Vanderlinden B, et al. Diagnostic accuracy of 89Zr-rituximab-PET/CT imaging in patients with relapsed CD20+ B-cell non-Hodgkin’s lymphoma: comparison with 18FDG-PET/CT. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP424.
17.
Kluge R. PET in pediatric solid tumors with the focus on the evaluation of response to therapy. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP528.
18.
Pfluger T. Imaging of neuroblastoma beyond MIBG: PET, PET/CT, and MRI. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP527.
19.
Sabado C. PET in pediatric oncology. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP526.
20.
Votrubova J, Kabickova E, Jaruskova M, Belohlavek O, Sumerauer D, Kyncl M, et al. The role of FDG PET and PET/CT in initial staging of childhood lymphomas. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP431.
21.
Emonds LM, Swinnen JV, Vanderhoydonc F, Nuyts J, Mortelmans L, Mottaghy FM. Do androgens mediate the uptake of PET tracers in prostate cancer cell lines? Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP290.
22.
Giovacchini G, Picchio M, Garcia Parra R, Scattoni V, Gianolli L, Messa C, et al. PSA vs. PSA doubling time for prediction of [11C]choline PET/CT in prostatectomized prostate cancer patients with biochemical failure. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP080.
23.
Golemi A, Fuccio C, Santi I, Castellucci P, Maffione A, Schiavina R, et al. Prostate cancer patients with a single potentially treatable lesion at bone scintigraphy: 11C-choline PET/CT could have a role in the re-staging? Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP081.
24.
Fuccio C, Santi I, Castellucci P, Montini G, Schiavina R, Martorana G, et al. Correlation between 11C-choline PET/CT detection rate and trigger PSA in prostate cancer patients with an increase of PSA serum level after radical prostatectomy. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP082.
25.
Balogova S, Huchet V, Gutman F, Kerrou K, Nataf V, Montravers F, et al. Fluoromethylcholine (18F) (FCH) PET/CT for the detection of hepatocellular carcinoma (HCC) in patients with a chronic liver disease and liver nodules: prospective comparison with FDG (18F) PET/CT. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP101.
26.
Erlich F, Camisao C, Almeida SA, Nogueira-Rodrigues A, Ferreira CG, Mamede M. PET-image tumor delineation in cervical cancer: threshold contouring and lesion volumes. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP352.
27.
Van Elmpt W, Dekker A, Lambin P, De Ruysscher D, Öllers M. Investigation of 3D PET, 4D PET and a new breathing amplitude reconstruction algorithm for tumour characterization in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP353.
28.
Schmidt MC, Tossios P, Müller-Ehmsen J, Ünal N, Scheid C, Erdmann E, et al. Effect of aortocoronary bypass surgery in combination with bone marrow cell injection on infarct size after myocardial infarction: are there differences between transmural and nontransmural infarcts? Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP286.
29.
Wendler T, Herrmann K, Schnelzer A, Lasser T, Traub J, Kutter O, et al. Clinical introduction of freehand SPECT for image-guided sentinel lymph node biopsy. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP022.
30.
Vermeeren L, Valdés Olmos R, Meinhardt W, Vogel W, Hoefnagel K, Bex A, et al. Abdominal para-aortic sentinel lymph nodes: towards optimal detection and intra-operative localization using SPECT/CT and intra-operative real-time imaging. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:PW114.
31.
Vermeeren L, Klop M, Valdés Olmos R, Balm F, van den Brekel M. SPECT/CT and portable gamma camera; an innovative combination for sentinel node detection in oral cavity carcinoma. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP608.
32.
Mariscal E, Roca I, Sáez M, Dellepiane F, Fuertes J, Aguadé S, et al. Routine use of sentinel lymph node biopsy in squamous cell head and neck cancer. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP365.
33.
Mariscal E, Roca I, Sabadell D, Dellepiane F, Barios M, Aguadé S, et al. SPECT-CT sentinel lymph node in breast cancer. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP018.
34.
Ilgan S, Ozturk E, Yıldız R, Emer O, Ayan A, Gorgulu S, et al. Combination of preoperative ultrasonographic mapping and radioguided occult lesion localization in patients with locally recurrent/persistent papillary thyroid carcinoma: a practical method for central compartment reoperation. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP556.
35.
Papp L, Zuhayra M, Zsoter N, Szabo G, Henze E. Automated triple fusion of Na-I SPECT/CT and MDP SPECT image triples for thyroid carcinoma localizations. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP493.
36.
Steiner C, Vees H, Wissmeyer M, Chouiter A, Velasquez M, Namy S, et al. Work-up before pelvic radiotherapy treatment planning using multimodality imaging in prostate cancer: combined SPECT/CT lymphoscintigraphy and 18F-choline PET/CT. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:P315.
37.
Tanwar J, Datta A, Chuttani K, Mishra AK. Facile synthesis of methionine conjugate with macrocyclic chelate (DO3A-Act-Met): its preclinical evaluation as SPECT/PET radiopharmaceutical for tumor imaging. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP434.
38.
Barrett JA, LaFrance ND, Coleman R, Goldsmith SJ, Stubbs JB, Petry NA, et al. Targeting metastatic prostate cancer (PCa) using 123I-MIP-1072 and 123I-MIP-1095: a phase I clinical study in patients. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP436.
39.
Brillouet S, Dorbes S, Mestre-Voegtlé B, Nalis J, Dierickx L, Caselles O, et al. Preclinical evaluation of new radioligands of cholecystokinin/gastrin receptors. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP480.
40.
Chérel M, Gouard S, Gaignerie A, Gaschet J, Bigot-Corbel E, Faivre-Chauvet A, et al. Targeting the CD138 antigen for the treatment of multiple myeloma with bismuth-213. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP259.
41.
Wild R, Korkmaz Z, Stripecke R, Sundarasetty BS, Knapp WH, Petrich T. Stable expression of the sodium/iodide symporter (NIS) for gene therapy using a novel lentiviral vector system. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP258.
42.
Mattone V, Sarti G, Fabbri C, Casi M, Agostini M, De Lauro F, et al. Peptide receptor radionuclide therapy with 90Y-DOTATOC in neuroendocrine tumours: correlation between radiobiological parameters and clinical outcomes in 50 patients. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:PW042.
43.
Naji M, Welsh SJ, Zhao C, Meades R, Al-Nahhas A. 68Ga-DOTATATE PET vs. 123I-MIBG in the detection of malignant neuroectodermal tumours. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP552.
44.
Ambrosini V, Campana D, Bodei L, Nanni C, Musto A, Castellucci P, et al. 68Ga-DOTA-NOC PET: clinical impact in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:PW095.
45.
Herbertson R, Tebbutt N, Lee F, Gill S, Chapell B, Cavicchiolo T, et al. Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP531.
46.
Boucek JA, Turner J. Personalized dosimetry of 131I-rituximab radioimmunotherapy of lymphoma. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP534.
47.
Di Dia A, Botta F, Ferrari M, Sarnelli A, Cremonesi M, De Cicco C, et al. 3D dosimetry with standard and voxel MIRD methods on Intraoperative Avidinination for Radionuclide Therapy (IART®) to evaluate absorbed dose and radiobiological effects. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP509.
48.
Rühl R, Denecke T, Pech M, Seidensticker M, Kettner E, Hildebrandt B, et al. Safety and efficacy of 90Y microsphere therapy in CRC patients with liver dominant metastases failing multiple lines of systemic chemotherapy: a matched pair analysis. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP345.
49.
Payoux P, Gantet P, Itti E, Zanotti Fregonara P, Kas A, Habert MO, et al. Partial volume effect correction reduces multi-centre variability in dopaminergic SPECT quantification. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP394.
50.
Drzezga A. Voxel by voxel analysis in clinical perfusion and metabolism. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP395.
51.
Hammers A, Heckemann RA. Construction and use of atlas image databases. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP396.
52.
Van Paesschen W. Ictal SPECT in the presurgical evaluation of refractory partial epilepsy. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP397.
53.
Herholz K. Targets interesting for dementia. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP523.
54.
Halldin C. Imaging tracers. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP524.
55.
Tatsch K. Clinical imaging. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP525.
56.
Van Laere K, Vandenberghe R, Law I, Brooks D, Thurfjell L, Farrah G, et al. Uptake of [18F]Flutemetamol in Healthy Volunteer, Alzheimer's disease and mild cognitive Impairment subjects in a phase II clinical trial. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP145.
57.
Barthel H, Becker G, Luthardt J, Patt M, Hammerstein E, Hartwig K, et al. BAY 94-9172-A promising 18F-labeled β-amyloid plaque PET tracer for in vivo diagnosis of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP054.
58.
Okamura N, Furumoto S, Tashiro M, Funaki Y, Kikuchi A, Shiga Y, et al. [11C]BF-227 PET study in protein conformational diseases. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:P355.
59.
Kendziorra K, Meyer P, Wolf H, Hesse S, Barthel H, Seese A, et al. Cerebral nicotinic acetylcholine receptors (nAChRs) in patients with Alzheimer’s disease (AD) assessed with 2-[18F]F-A85380 (2FA) PET. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP055.
60.
Förster S, Buschert VC, Buchholz H, Teipel SJ, Zach C, Hampel H, et al. Effects of a 6-months stage-specific cognitive intervention program on brain metabolism in subjects with amnestic mild cognitive impairment (aMCI) and mild Alzheimer’s disease (AD). Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP048.
61.
Staff RT, Murray AD, Ahearn TS, Bentham P, Wischik C. SPECT and PET changes in those receiving Alzheimer's disease (AD) Tau therapy rember™ (Methythioninium chloride). Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP051.
62.
Tatsch K, Varrone A, Tossici-Bolt L, Dickson JC, Sera T, Darcourt J, et al. ENCDAT – European database of I-123-FP-CIT SPECT scans of healthy controls: first results. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP306.
63.
Catafau AM, Searle G, Bullich S, Gunn RN, Rabiner E, Herance R, et al. [11C]NNC112: a selective PET ligand for in-vivo imaging of dopamine D1 receptors? A human study with ketanserin challenge. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP502.
64.
Finnema SJ, Varrone A, Hwang T, Gulyas B, Pierson E, Farde L, et al. The 5-HT1B radioligand [11C]AZ10419369 is sensitive to endogenous serotonin levels in vivo. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP338.
65.
Bresch A, Hesse C, Luthardt J, Nägler K, Schönknecht P, Meyer PM, et al. In vivo serotonin transporter (SERT) – availability in patients with first depressive episode. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP170.
66.
Hesse S, Regenthal R, Nägler K, Knüpfer H, Bresch A, Luthardt J, et al. In vivo serotonin transporter (SERT) availability and genotype in patients with depressive disorder. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP171.
67.
Asenbaum S, Assem-Hilger E, Savli M, Hoffmann M, Mien K, Mitterhauser M, et al. [11C] WAY-100635 and [18F] FDG PET in temporal lobe epilepsy. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP175.
68.
Varrone A, Steiger C, Toth M, Takano A, Guilloteau D, Gulyás B, et al. Kinetic analysis and quantification of the dopamine transporter in the non-human primate brain with [11C]PE2I and [18F]FE-PE2I. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP342.
69.
Evens N, Vandeputte C, Toelen J, Baekelandt V, Debyser Z, Verbruggen A, et al. Validation of PET radioligands for visualisation of the type 2 cannabinoid receptor in a rat model with local cerebral CB2R overexpression. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP337.
70.
Fuster V. Diagnosing early atherothrombotic disease in the XXI century. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP007d.
71.
Chauvet C, Cachin F, Lipiecki J, Casset-Senon D, Thouly C, Boyer L, et al. New integrated software for simultaneous analysis of myocardial perfusion SPECT and coronary CT angiography: feasibility study. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP222.
72.
Laitinen IE, Marjamäki P, Någren K, Virsu P, Laine JO, Ylä-Herttuala S, et al. [11C]Choline accumulates in atherosclerotic plaques in mice. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:P050.
73.
Wong Y, Raijmakers P, Lubberink M, Westerhof N, Vonk-Noordegraaf A. Hyperemic myocardial blood flow assessment of the right and left ventricle by supine exercise in PET. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP470.
74.
Evangelista L, Acampa W, Ferro A, Daniele S, Xhoxhi E, De Rimini ML, et al. Impact of inducible ischemia by stress SPECT in cardiac risk assessment in diabetic patients: results of a prospective, multicenter trial. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP146.
75.
Evangelista L, Acampa W, Ferro A, Daniele S, Xhoxhi E, De Rimini ML, et al. Role of SPECT imaging in the definition of likelihood of coronary artery disease in diabetic patients: results of a prospective, multicenter trial. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP588.
76.
Andersen KF, Alslev L, Zerahn B, Hasbak P. Pre-risk assessment of CHD: coronary artery calcium score compared with Framingham score and Copenhagen risk score in a Danish population (preliminary results). Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:PW084.
77.
Fallahi B, Beiki D, Bostani M, Fard-Esfahani A, Eftekhari M, Mandegar MH, et al. Value of single injection-double acquisition stress gated SPECT before and during low-dose dobutamine infusion for prediction of myocardial perfusion and function improvement after coronary artery bypass graft. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP223.
78.
Thakur M. Imaging infection: challenges and prospects. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP202c.
79.
Bajc M. Ventilation/perfusion: SPECT vs (SPECT/)CTA. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP007b.
80.
Frokiaer J. The value of renography in hydronephrosis: physiology and pathophysiology. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP330.
81.
Garcia-Fontecha C, Barber I, Roca I. The actual role of bone scan in paediatrics. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP269–71.
82.
Bajc M. Clinical impact of ventilation/perfusion SPECT. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP196.
83.
Picard D, Chartrand R, Picard M. Tomographic pulmonary ventilation / perfusion scan is highly predictive in the diagnosis of pulmonary embolism. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP611.
84.
Papandrianos N, Kalogeropoulou C, Spyridonidis T, Zabakis P, Savvopoulos C, Lakiotis V, et al. SPECT/low resolution CT sestamibi scintigraphy compared to four-dimensional CT for parathyroid localization in primary hyperparathyroidism. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP215.
85.
Miot-Noirault E, Vidal A, Gouin F, Auzeloux P, Moins N, Maublant J, et al. Experimental validation of 99mTc-NTP 15-5 as a SPECT radiotracer for in vivo assessment of degenerative and tumoural pathologies of cartilage. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP423.
86.
Angelides S, Manolios N, Kumar V, Englert H, Sam L, Preston P, et al. 99mTc-Labelled ECDG in the evaluation of disease activity in rheumatic conditions. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP462.
87.
Tralhao JG, Abrantes AM, Oliveiros B, Cardoso D, Martins M, Carvalho C, et al. Liver regeneration and its clinical impact. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP343d.
88.
Piccardo A, Foppiani L, Calafiore L, Hanau G, Bianchi P, Arlandini A, et al. Second thyroid tumor in patients treated with radiotherapy in childhood for primary malignancy. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP246.
89.
Estorch M, Camacho V, Fraga G, Rivera E, Artigas C, RodríguezRevuelto A, et al. Clinical impact of renal DMSA scintigraphy performed during acute urinary tract infection. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP248.
90.
Andersson J, Varnäs K, Cselényi Z, Gulyás B, Swahn B, Finnema S, et al. Development of an improved amyloid probe, [11C]AZD2184. From pre-clinical to clinical in vivo PET measurements in AD patients. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP410.
91.
Marton J, Schoultz BW, Hjørnevik T, Drzezga A, Wester HJ, Willoch F, et al. 11C-Phenethyl-orvinol: a full agonist diprenorphine analogue for PET-imaging of opioid receptors. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP412.
92.
Celen S, De Angelis M, Chitneni SK, Alcazar J, Koole M, Dedeurwaerdere S, et al. Synthesis and preliminary biological evaluation of [18F]JNJ41510417 as a radioligand for positron emission tomography imaging of phosphodiesterase-10A in the brain. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP411.
93.
Baumann CA, Mu L, Johannsen S, Lucatelli C, Honer M, Schubiger AP, et al. Development of novel fluorine-18 labeled PET tracers for imaging the metabotropic glutamate receptor subtype 5 (mGluR5). Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP266.
94.
Di Gialleonardo V, de Vries EF, Chianelli M, Wolffenbuttel BH, De Vos P, Pozzilli P, et al. 18F-Interleukin-2, a novel radioactive probe for insulitis imaging by PET. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP281.
95.
Bruchertseifer F, Morgenstern A, Friesen C, Roscher M, Miltner E, Pfost B, et al. In vitro and in vivo comparison of 226Th- and 213Bi-labelled radioconjugates for targeted alpha therapy. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP627.
96.
Orlova A, Ekblad C, Abrahmsén L, Wennborg A, Frejd FY, Tolmachev V. In vivo evaluation of site-specifically labelled ABD-fused anti-HER2 Affibody molecule for radionuclide therapy. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP385.
97.
Mikkola K, Arponen E, Fagerholm V, Nuutila P, Haaparanta M. Intrapancreatic distribution and metabolism of 11Cdihydrotetrabenazine in rat. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP422.
98.
Britten A. New equipment and future perspectives. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP008.
99.
Chatal J. New horizons in nuclear medicine therapy. Eur J Nucl Med Mol Imaging 2009;36 Suppl 2:OP009.
Metadata
Title
Highlights of the EANM Congress Barcelona 2009: increasing our impact in diagnostic imaging
Author
Isabel Roca
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1374-8

Other articles of this Issue 4/2010

European Journal of Nuclear Medicine and Molecular Imaging 4/2010 Go to the issue

Focus on

Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma

Original Article

Long-term prognostic value of early poststress 99mTc-tetrofosmin lung uptake during exercise (SPECT) myocardial perfusion imaging

Original Article

Significance of cardiac sympathetic nervous system abnormality for predicting vascular events in patients with idiopathic paroxysmal atrial fibrillation

Erratum

Erratum to: Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm

Original Article

18F-FDG PET in stage IB/IIB cervical adenocarcinoma/adenosquamous carcinoma

Guidelines

Guidelines for the labelling of leucocytes with 111In-oxine